Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants

European Journal of Clinical Pharmacology

Volumn 71, Issue 5, 2015, Pages 611-615

  Sicard, Mélanie ^a   Launay, Elise ^a   Caillon, Jocelyne ^a   Jacqueline, Cédric ^a   Legrand, Arnaud ^a   Deslandes, Guillaume ^a   Navas, Dominique ^a   Rozé, Jean Christophe ^a   Guen, Christèle Gras Le ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Linezolid; Pharmacokinetics; Premature infants

Indexed keywords

ANTIINFECTIVE AGENT; LINEZOLID;

BLOOD; DRUG EFFECTS; FEMALE; GESTATIONAL AGE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN; ORAL DRUG ADMINISTRATION; PREMATURITY; RETROSPECTIVE STUDY; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INJECTIONS, INTRAVENOUS; LINEZOLID; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; TREATMENT OUTCOME;

EID: 84939982600     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1813-3     Document Type: Article

References (20)

1. ANAES (2002) Recommandation pour la pratique clinique: Diagnostic et traitement curatif de l'infection bactérienne précoce du nouveau-né
2. Beiras-Fernandez A, Vogt F, Sodian R et al (2010) Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect Drug Resist 3:95-101
3. Cohen-Wolkowiez M, Moran C, Benjamin DK et al (2009) Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J 28:1052-1056
4. Fratarelli DAC, Ergun H, Lulic-Botica M et al (2005) Vancomycin elimination in human infants with intra uterine growth retardation. Pediatr Infect Dis J 24:979-983
5. French G (2003) Safety and tolerability of linezolid. J Antimicrob Chemother 51(S2):ii45-ii53
6. Guellec I, Lapillonne A, Renolleau S et al (2011) Neurological outcomes at school age in very preterm infants born with severe or mild growth restriction. Pediatrics 127:e883-e891
7. Honzik T, Wenchich L, Böhm M et al (2006) Activities of respiratory chain complexes and pyruvate dehydrogenase in isolated muscle mitochondria in premature neonates. Early Hum Dev 84:269-276
8. Jacqueline C, Batard E, Perez L et al (2002) In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 46:3706-3711
9. Jones RN, Stilwell MG, Hogan PA et al (2007) LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diag Microbiol Infect Dis 309-317
10. Jungbluth GL, Welshman IR, Hopkins NK (2003) Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 22:S153-S157
11. Kaplan SL, Deville JG, Yogev R et al (2003) Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 22:677-685
12. Kearns GL, Jungbluth GL, Abdel-Rahman SM et al (2003) Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 74:413-422
13. McKamy S, Hernandez E, Jahng M et al (2011) Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 158:422-426
14. Meissner HC, Towsend T, Wenman W et al (2003) Hematologic effects of linezolid in young children. Pediatr Infect Dis J 22:S186-S192
15. Saiman L, Goldfarb J, Kaplan SA et al (2003) Safety and tolerability of linezolid in children. Pediatr Infect Dis J 22:S193-S200
16. Sohn AH, Garrett DO, Sinkowitz-Cochran RL et al (2001) Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the First National Point-Prevalence Survey. J Pediatr 139:821-827
17. Su E, Crowley K, Carcillo JA, Michaels MG (2011) Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J 30:804-806
18. Swaney SM, Aoki H, Ganoza MC et al (1998) The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42(12):3251-3255
19. Van den Hoogen A, Gerards LJ, Verboon-Maciolek MA et al (2010) Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents. Neonatology 97:22-28
20. Vardakas KZ, Ntziora F, Falagas ME (2007) Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 8:2381-2400